Effects of interleukin-2 in immunostimulation and immunosuppression

De novo design of potent and selective mimics of IL-2 and IL-15

(2019) Daniel-Adriano Silva et al.   NATURE

IL2/anti-IL2 complex combined with CTLA-4, but not PD-1, blockade rescues antitumor NK cell function by regulatory T-cell modulation

(2019) Pamela Caudana et al.   Cancer Immunology Research

Innate lymphoid cells support regulatory T cells in the intestine through interleukin-2

(2019) Lei Zhou et al.   NATURE

Systemic IL-2/anti-IL-2Ab complex combined with sublingual immunotherapy suppresses experimental food allergy in mice through induction of mucosal regulatory T cells

(2018) P. L. Smaldini et al.   ALLERGY

Signaling and Function of Interleukin-2 in T Lymphocytes

(2018) Sarah H. Ross et al.   Annual Review of Immunology

Cancer immunotherapy beyond immune checkpoint inhibitors

(2018) Julian A. Marin-Acevedo et al.   Journal of Hematology & Oncology

Blocking IL-2 Signal In Vivo with an IL-2 Antagonist Reduces Tumor Growth through the Control of Regulatory T Cells

(2018) Tania Carmenate et al.   JOURNAL OF IMMUNOLOGY

A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism

(2018) Eleonora Trotta et al.   NATURE MEDICINE

Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes

(2018) Jonathan T. Sockolosky et al.   SCIENCE

TCR Signaling: Mechanisms of Initiation and Propagation

(2018) Adam H. Courtney et al.   TRENDS IN BIOCHEMICAL SCIENCES

Langerhans Cells Prevent Autoimmunity via Expansion of Keratinocyte Antigen-Specific Regulatory T Cells

(2018) Daniela Y. Kitashima et al.   EBioMedicine

A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease

(2018) Laurence B. Peterson et al.   JOURNAL OF AUTOIMMUNITY

IL-2/CD25: A Long-Acting Fusion Protein That Promotes Immune Tolerance by Selectively Targeting the IL-2 Receptor on Regulatory T Cells

(2018) Natasha C. Ward et al.   JOURNAL OF IMMUNOLOGY

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance

(2018) Michael M. Boyiadzis et al.   Journal for ImmunoTherapy of Cancer

Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice

(2017) Megan Lo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia

(2017) Liuluan Zhu et al.   Journal of Hematology & Oncology

Deal watch: IL-2 focus switches to stimulating Tregs

(2017) Megan Cully   NATURE REVIEWS DRUG DISCOVERY

Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells

(2017) Rodrigo Vazquez-Lombardi et al.   Nature Communications

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines

(2017) Christian Klein et al.   OncoImmunology

Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy

(2017) Deborah Charych et al.   PLoS One

Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease

(2016) John Koreth et al.   BLOOD

Regulatory T cells delay disease progression in Alzheimer-like pathology

(2016) Cira Dansokho et al.   BRAIN

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma

(2016) Ajjai Alva et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models

(2016) D. H. Charych et al.   CLINICAL CANCER RESEARCH

Restoring regulation – IL-2 therapy in systemic lupus erythematosus

(2016) Jens Y. Humrich et al.   Expert Review of Clinical Immunology

Pleiotropic Effects of IL-2 on Cancer: Its Role in Cervical Cancer

(2016) Arturo Valle-Mendiola et al.   MEDIATORS OF INFLAMMATION

An essential role for the IL-2 receptor in Treg cell function

(2016) Takatoshi Chinen et al.   NATURE IMMUNOLOGY

Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus

(2016) Jing He et al.   NATURE MEDICINE

IL2Rβ-dependent signals drive terminal exhaustion and suppress memory development during chronic viral infection

(2016) Jean-Christophe Beltra et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2

(2016) N. Arenas-Ramirez et al.   Science Translational Medicine

Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial

(2016) John A. Todd et al.   PLOS MEDICINE

Spontaneous Resolution of Acute Rejection and Tolerance Induction With IL-2 Fusion Protein in Vascularized Composite Allotransplantation

(2015) R. Jindal et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Immunoendocrine dysbalance during uncontrolled T. cruzi infection is associated with the acquisition of a Th-1-like phenotype by Foxp3+ T cells

(2015) Florencia B. González et al.   BRAIN BEHAVIOR AND IMMUNITY

Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study

(2015) Riccardo Danielli et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Emerging Roles of CCCH-Type Zinc Finger Proteins in Destabilizing mRNA Encoding Inflammatory Factors and Regulating Immune Responses

(2015) Chuanbin Yang et al.   CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION

Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms

(2015) Jamie B. Spangler et al.   IMMUNITY

Interleukin-2 Activity Can Be Fine Tuned with Engineered Receptor Signaling Clamps

(2015) Suman Mitra et al.   IMMUNITY

Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells

(2015) Charles J.M. Bell et al.   JOURNAL OF AUTOIMMUNITY

NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy

(2015) Michel M van den Heuvel et al.   Journal of Translational Medicine

Adoptive cell transfer as personalized immunotherapy for human cancer

(2015) S. A. Rosenberg et al.   SCIENCE

Ultra Low-Dose IL-2 for GVHD Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation Mediates Expansion of Regulatory T Cells without Diminishing Antiviral and Antileukemic Activity

(2014) A. A. Kennedy-Nasser et al.   CLINICAL CANCER RESEARCH

IL-2 Phosphorylates STAT5 To Drive IFN-  Production and Activation of Human Dendritic Cells

(2014) F. Herr et al.   JOURNAL OF IMMUNOLOGY

Identification of STAT5A and STAT5B Target Genes in Human T Cells

(2014) Takahiro Kanai et al.   PLoS One

Effects of Low-Dose Recombinant Interleukin 2 to Promote T-Regulatory Cells in Alopecia Areata

(2014) Emeline Castela et al.   JAMA Dermatology

A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors

(2013) Joseph P Connor et al.   BMC CANCER

Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity

(2013) Kevin Goudy et al.   CLINICAL IMMUNOLOGY

Limitations of IL-2 and Rapamycin in Immunotherapy of Type 1 Diabetes

(2013) Audrey Baeyens et al.   DIABETES

Regulation of Foxp3+ Inducible Regulatory T Cell Stability by SOCS2

(2013) C. A. Knosp et al.   JOURNAL OF IMMUNOLOGY

Active STAT5 Regulates T-bet and Eomesodermin Expression in CD8 T Cells and Imprints a T-bet-Dependent Tc1 Program with Repressed IL-6/TGF- 1 Signaling

(2013) M. Grange et al.   JOURNAL OF IMMUNOLOGY

Human IL-2 Mutein with Higher Antitumor Efficacy Than Wild Type IL-2

(2013) T. Carmenate et al.   JOURNAL OF IMMUNOLOGY

T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein

(2013) Julien Laurent et al.   Journal of Translational Medicine

Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease

(2013) K.-i. Matsuoka et al.   Science Translational Medicine

Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial

(2013) Agnès Hartemann et al.   Lancet Diabetes & Endocrinology

Role of Cytokines in Thymus- Versus Peripherally Derived-Regulatory T Cell Differentiation and Function

(2013) Jérémie David Goldstein et al.   Frontiers in Immunology

Phase II trial of hu14.18-IL2 for patients with metastatic melanoma

(2012) Mark R. Albertini et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Cytokine Therapy With Interleukin-2/Anti–Interleukin-2 Monoclonal Antibody Complexes Expands CD4+CD25+Foxp3+ Regulatory T Cells and Attenuates Development and Progression of Atherosclerosis

(2012) Tam Nguyen Dinh et al.   CIRCULATION

Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs  -Cell Function

(2012) S. A. Long et al.   DIABETES

A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours

(2012) Silke Gillessen et al.   EUROPEAN JOURNAL OF CANCER

Interleukin-2 Inhibits Germinal Center Formation by Limiting T Follicular Helper Cell Differentiation

(2012) André Ballesteros-Tato et al.   IMMUNITY

Effects of an agonist interleukin-2/Fc fusion protein, a mutant antagonist interleukin-15/Fc fusion protein, and sirolimus on cardiac allograft survival in non-human primates

(2012) Timothy Millington et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’

(2012) Aron M. Levin et al.   NATURE

Interleukin-2 Production by Dendritic Cells and its Immuno-Regulatory Functions

(2012) Teresa Zelante et al.   Frontiers in Immunology

A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma

(2011) T. K. Eigentler et al.   CLINICAL CANCER RESEARCH

Mast Cell Interleukin-2 Production Contributes to Suppression of Chronic Allergic Dermatitis

(2011) Alon Y. Hershko et al.   IMMUNITY

CD4+CD25+Foxp3+ Regulatory T Cells Promote Th17 Cells In Vitro and Enhance Host Resistance in Mouse Candida albicans Th17 Cell Infection Model

(2011) Pushpa Pandiyan et al.   IMMUNITY

T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells

(2011) Guoyan Cheng et al.   IMMUNOLOGICAL REVIEWS

Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages

(2011) Wei Liao et al.   NATURE IMMUNOLOGY

Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5

(2011) Xiang-Ping Yang et al.   NATURE IMMUNOLOGY

A role for interleukin-2 trans-presentation in dendritic cell–mediated T cell activation in humans, as revealed by daclizumab therapy

(2011) Simone C Wuest et al.   NATURE MEDICINE

Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis

(2011) David Saadoun et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease

(2011) John Koreth et al.   NEW ENGLAND JOURNAL OF MEDICINE

The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma

(2010) Manfred Johannsen et al.   EUROPEAN JOURNAL OF CANCER

Prolonged Interleukin-2Rα Expression on Virus-Specific CD8+ T Cells Favors Terminal-Effector Differentiation In Vivo

(2010) Vandana Kalia et al.   IMMUNITY

Interleukin-2 and Inflammation Induce Distinct Transcriptional Programs that Promote the Differentiation of Effector Cytolytic T Cells

(2010) Matthew E. Pipkin et al.   IMMUNITY

IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells

(2010) Yenkel Grinberg-Bleyer et al.   JOURNAL OF EXPERIMENTAL MEDICINE

IL-2 mRNA Stabilization upon PMA Stimulation Is Dependent on NF90-Ser647 Phosphorylation by Protein Kinase C I

(2010) P. Zhu et al.   JOURNAL OF IMMUNOLOGY

Paradoxical glomerular filtration of carbon nanotubes

(2010) A. Ruggiero et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor   subunit CD25

(2010) S. Letourneau et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells

(2010) C. Krieg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironments

(2010) D. Busse et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cytokine-Producing Effector B Cells Regulate Type 2 Immunity to H. polygyrus

(2009) Wojciech Wojciechowski et al.   IMMUNITY

A Low Interleukin-2 Receptor Signaling Threshold Supports the Development and Homeostasis of T Regulatory Cells

(2009) Aixin Yu et al.   IMMUNITY

The T-cell-receptor signaling network

(2009) M. Huse   JOURNAL OF CELL SCIENCE

In vivo expansion of T reg cells with IL-2–mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression

(2009) Kylie E. Webster et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Engineered Interleukin-2 Antagonists for the Inhibition of Regulatory T Cells

(2009) David V. Liu et al.   JOURNAL OF IMMUNOTHERAPY

Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function

(2009) Maciej Kmieciak et al.   Journal of Translational Medicine

Bcl6 and Blimp-1 Are Reciprocal and Antagonistic Regulators of T Follicular Helper Cell Differentiation

(2009) R. J. Johnston et al.   SCIENCE

Janus-Kinase-3-Dependent Signals Induce Chromatin Remodeling at the Ifng Locus during T Helper 1 Cell Differentiation

(2008) Min Shi et al.   IMMUNITY

Central Role of Defective Interleukin-2 Production in the Triggering of Islet Autoimmune Destruction

(2008) Qizhi Tang et al.   IMMUNITY

Primary Immune Deficiency Disorders Presenting as Autoimmune Diseases: IPEX and APECED

(2008) D. Moraes-Vasconcelos et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Priming for T helper type 2 differentiation by interleukin 2–mediated induction of interleukin 4 receptor α-chain expression

(2008) Wei Liao et al.   NATURE IMMUNOLOGY

The Biology of Interleukin-2

(2007) Thomas R. Malek   Annual Review of Immunology